Subtyping Pancreatic Cancer

被引：35

作者：

Biankin, Andrew V. ^{[1
,2
,3
,4
]}

Maitra, Anirban ^{[5
]}

机构：

[1] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Inst Canc Sci, Glasgow G61 1BD, Lanark, Scotland

[2] Glasgow Royal Infirm, West Scotland Pancreat Unit, Glasgow G31 2ER, Lanark, Scotland

[3] Garvan Inst Med Res, Kinghorn Canc Ctr, Canc Div, Sydney, NSW 2010, Australia

[4] Univ NSW, Fac Med, South Western Sydney Clin Sch, Liverpool, NSW 2170, Australia

[5] Univ Texas MD Anderson Canc Ctr, Sheikh Ahmed Ctr Pancreat Canc Res, Pathol & Translat Mol Pathol, Houston, TX 77030 USA

来源：

CANCER CELL | 2015年 / 28卷 / 04期

基金：

英国惠康基金;

关键词：

THERAPY;

D O I：

10.1016/j.ccell.2015.09.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The complex tumor microenvironment can make molecularly subtyping cancer using mRNA expression challenging, particularly for cancers with low epithelial content, such as pancreatic cancer. In a recent edition of Nature Genetics, Moffitt and colleagues show that subtracting normal epithelial transcripts can provide insights into the molecular pathology of pancreatic cancer.

引用

页码：411 / 413

页数：4

共 50 条

[1] Subtyping for pancreatic cancer precision therapy
Huang, Xing
Zhang, Gang
Liang, Tingbo
[J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 482 - 494
[2] Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, Fieke E. M.
Casolino, Raffaella
Pea, Antonio
Biankin, Andrew V.
Chang, David K.
[J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (01) : 1 - 13
[3] Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
Pishvaian, Michael J.
Brody, Jonathan R.
[J]. ONCOLOGY-NEW YORK, 2017, 31 (03): : 159 - 168
[4] Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Xu, Zhou
Hu, Kai
Bailey, Peter
Springfeld, Christoph
Roth, Susanne
Kurilov, Roma
Brors, Benedikt
Gress, Thomas
Buchholz, Malte
An, Jingyu
Wei, Kongyuan
Peccerella, Teresa
Buechler, Markus W.
Hackert, Thilo
Neoptolemos, John P.
[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
[5] The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer
Dreyer, Stephan B.
Rae, Sarah
Bisset, Kirsty
Upstill-Goddard, Rosie
Gemenetzis, Georgios
Johns, Amber L.
Dickson, Euan J.
Mittal, Anubhav
Gill, Anthony
Duthie, Fraser T.
Pea, Antonio
Lawlor, Rita
Scarpa, Aldo
Salvia, Roberto
Pulvirenti, Alessandra
Zerbi, Alessandro J.
Marchesi, Federica V.
McKay, Colin S.
Biankin, Andrew K.
Samra, Jaswinder B.
Chang, David K.
Jamieson, Nigel
[J]. ANNALS OF SURGERY, 2023, 277 (02) : E396 - E405
[6] Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer
Collisson, Eric A.
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4715 - 4716
[7] Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer
Mehla, Kamiya
Singh, Pankaj K.
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (01) : 6 - 8
[8] CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids
Hennig, Alexander
Wolf, Laura
Jahnke, Beatrix
Polster, Heike
Seidlitz, Therese
Werner, Kristin
Aust, Daniela E.
Hampe, Jochen
Distler, Marius
Weitz, Juergen
Stange, Daniel E.
Welsch, Thilo
[J]. STEM CELLS INTERNATIONAL, 2019, 2019
[9] Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic
Du, Yongxing
Zhao, Bangbo
Liu, Ziwen
Ren, Xiaoxia
Zhao, Wenjing
Li, Zongze
You, Lei
Zhao, Yupei
[J]. JOURNAL OF CANCER, 2017, 8 (04): : 513 - 522
[10] Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy
Liu, Jingkai
Liu, Qiaofei
Zhang, Xiang
Cui, Ming
Li, Tong
Zhang, Yalu
Liao, Quan
[J]. CANCER CELL INTERNATIONAL, 2021, 21 (01)

← 1 2 3 4 5 →